Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Blopress Remained Top-selling Drug in 3rd Qtr: IMS Japan
December 11, 2006
- Larger Number of Patients per Facility Essential for Spearhead Medical Research: Dr Tanaka
December 11, 2006
- BUSINESS NEWS IN BRIEF
December 11, 2006
- R&D NEWS IN BRIEF
December 11, 2006
- SEMINAR
December 11, 2006
- Kenporen Preparing Pamphlet on Generic Drugs
December 11, 2006
- GENERIC NEWS IN BRIEF
December 11, 2006
- Terumo's Triplex Artificial Blood Vessel Recommended for Approval
December 11, 2006
- Criteria Established for "Observation Services"
December 11, 2006
- Companies Should Be Given Greater Freedom in Pricing New Drugs: Dr Aoki
December 4, 2006
- Industry Exchanges Opinions with Vice Minister of Health
December 4, 2006
- FJPWA Seminar
December 4, 2006
- Mediceo Paltac Holdings Aims for SGA Cost Ratio Below 6%: Mr Kumakura
December 4, 2006
- Drug Wholesaler Business Seminar
December 4, 2006
- SELF-MEDICATION NEWS IN BRIEF
December 4, 2006
- REGULATORY NEWS IN BRIEF
December 4, 2006
- Suzuken: Profits Up Due to Tough Stance in Price Negotiations
December 4, 2006
- 3 Anticancer Drug Candidates in PIIb: BI
December 4, 2006
- Toho: Historic High Net Profit "Not High Enough"
December 4, 2006
- New Clinical Trial Stimulus Plan to Be Announced in December: Mr Araki
December 4, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…